Summary of COVID-19 resveratrol studies
Studies
Meta Analysis
Hide extended summaries
RCT 100 outpatients in the USA, showing lower hospitalization and progression with resveratrol, without statistical significance.
Jun 2022, Scientific Reports, https://www.nature.com/articles/s41598-022-13920-9, https://c19p.org/mccreary3
Retrospective 230 severe COVID-19 patients in India, showing lower mortality with resveratrol + copper, without statistical significance. This study followed preclinical data showing that sepsis-related cytokine storm and fatality in mice could be prevented with oral administration of resveratrol and copper.
Jul 2020, medRxiv, https://www.medrxiv.org/content/10.1101/2020.07.21.20151423, https://c19p.org/mittra
30 patient resveratrol late treatment RCT: 14% higher ventilation (p=1), 14% higher ICU admission (p=1), and 14% higher hospitalization (p=1).
Small RCT of zinc plus resveratrol in COVID-19+ outpatients, showing no significant differences in viral clearance or symptoms. Although the treatment group was older (46.3 vs. 38.5) and had more severe baseline symptoms, they had similar symptomatic recovery by the second week.
Sep 2021, SSRN, https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3934228, https://c19p.org/kaplanrsv
1. McCreary et al., Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19)
100 patient resveratrol early treatment RCT: 67% lower hospitalization (p=0.62) and 43% lower progression (p=0.52).RCT 100 outpatients in the USA, showing lower hospitalization and progression with resveratrol, without statistical significance.
Jun 2022, Scientific Reports, https://www.nature.com/articles/s41598-022-13920-9, https://c19p.org/mccreary3
2. Mittra et al., Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002)
230 patient resveratrol late treatment study: 44% lower mortality (p=0.06).Retrospective 230 severe COVID-19 patients in India, showing lower mortality with resveratrol + copper, without statistical significance. This study followed preclinical data showing that sepsis-related cytokine storm and fatality in mice could be prevented with oral administration of resveratrol and copper.
Jul 2020, medRxiv, https://www.medrxiv.org/content/10.1101/2020.07.21.20151423, https://c19p.org/mittra
30 patient resveratrol late treatment RCT: 14% higher ventilation (p=1), 14% higher ICU admission (p=1), and 14% higher hospitalization (p=1).
Small RCT of zinc plus resveratrol in COVID-19+ outpatients, showing no significant differences in viral clearance or symptoms. Although the treatment group was older (46.3 vs. 38.5) and had more severe baseline symptoms, they had similar symptomatic recovery by the second week.
Sep 2021, SSRN, https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3934228, https://c19p.org/kaplanrsv
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.